BridgeMD
New treatment option for Hip Osteoarthritis
Official title PENG Block and Delirium After Hip Arthroplasty
ClinicalTrials.gov ID: NCT07449468
What this study is testing
What is 0.2% ropivacaine?
0.2% ropivacaine is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for hip osteoarthritis.
Also referred to as PENG block with 0.2% ropivacaine.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Postoperative delirium is a common and serious complication in older adults undergoing total hip arthroplasty, associated with prolonged hospitalization, increased morbidity, delayed rehabilitation, and long-term cognitive decline. Modifiable perioperative risk factors include uncontrolled postoperative pain, opioid consumption, impaired early mobilization, and systemic inflammatory response.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 75 to 100
You may be able to join if
- Age ≥ 75 years
- Scheduled for elective primary total hip arthroplasty
- Planned spinal anesthesia
- ASA physical status II-III
- Ability to provide written informed consent
You likely can't join if
- Pre-existing delirium, acute psychosis, or active major psychiatric disorder
- Documented severe dementia or inability to provide informed consent
- Severe hearing or visual impairment preventing reliable CAM assessment
- Contraindications to regional anesthesia (e.g., coagulopathy according to institutional standards, infection at the injection site, allergy to local...
- Pre-existing neurological deficits of the operative lower limb are interfering with assessment
- Chronic opioid use (\>30 mg morphine milligram equivalents per day for \>2 weeks prior to surgery)
See the full eligibility criteria
- Age ≥ 75 years
- Scheduled for elective primary total hip arthroplasty
- Planned spinal anesthesia
- ASA physical status II-III
- Ability to provide written informed consent
- Ability to communicate and reliably assess pain using the Numeric Rating Scale (NRS)
- Expected postoperative hospitalization ≥ 72 hours
- Pre-existing delirium, acute psychosis, or active major psychiatric disorder
- Documented severe dementia or inability to provide informed consent
- Severe hearing or visual impairment preventing reliable CAM assessment
- Contraindications to regional anesthesia (e.g., coagulopathy according to institutional standards, infection at the injection site, allergy to local anesthetics)
- Pre-existing neurological deficits of the operative lower limb are interfering with assessment
- Chronic opioid use (\>30 mg morphine milligram equivalents per day for \>2 weeks prior to surgery)
- Severe renal impairment (eGFR \<30 mL/min/1.73 m²)
- Severe hepatic insufficiency
- Participation in another treatment clinical trial within 30 days
- Any other condition that, in the investigator's judgment, may interfere with study participation or protocol adherence
The study team makes the final eligibility decision.
Where it's taking place
- Poznan, Poland
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 75 years to 100 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Poznan, Poland. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.